Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 aTyr PharmaEnzon PharmaceuticalsBiondVax PharmaceuticalsAcorda TherapeuticsBioCardia
SymbolNASDAQ:LIFEOTCMKTS:ENZNNASDAQ:BVXVNASDAQ:ACORNASDAQ:BCDA
Price Information
Current Price$4.50$0.78$3.69$4.19$4.34
52 Week RangeBuyN/AN/AHoldBuy
MarketRank™
Overall Score1.50.60.51.42.0
Analysis Score3.50.00.03.03.5
Community Score2.32.82.52.25.0
Dividend Score0.00.00.00.00.0
Ownership Score0.80.00.00.00.8
Earnings & Valuation Score0.60.00.01.90.6
Analyst Ratings
Consensus RecommendationBuyN/AN/AHoldBuy
Consensus Price Target$15.67N/AN/A$23.67$9.25
% Upside from Price Target248.15% upsideN/AN/A464.84% upside113.13% upside
Trade Information
Market Cap$72.05 million$57.89 million$41.90 million$39.76 million$70.91 million
Beta2.170.772.410.751.98
Average Volume1,451,242299,277976,355965,015304,523
Sales & Book Value
Annual Revenue$420,000.00$210,000.00N/A$192.41 million$710,000.00
Price / Sales171.55275.66N/A0.2199.88
CashflowN/AN/AN/A$18.22 per shareN/A
Price / CashN/AN/AN/A0.23N/A
Book Value$5.40 per share$0.14 per share($2.88) per share$38.82 per share$0.35 per share
Price / Book0.835.57N/A0.1112.40
Profitability
Net Income$-23,600,000.00$-980,000.00$-31,600,000.00$-272,970,000.00$-14,710,000.00
EPS($7.03)N/A($3.60)($11.94)($2.61)
Trailing P/E RatioN/A0.00N/A0.76N/A
Forward P/E RatioN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net Margins-202.02%-1,711.94%N/A29.71%-5,103.95%
Return on Equity (ROE)-52.75%-20.29%N/A-8.60%-496.87%
Return on Assets (ROA)-38.40%-18.69%-135.18%-3.51%-178.90%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/AN/AN/A0.52%0.05%
Current Ratio4.76%8.91%6.48%1.09%1.99%
Quick Ratio4.76%8.91%6.48%0.88%1.99%
Ownership Information
Institutional Ownership Percentage55.82%N/A4.04%N/A9.01%
Insider Ownership Percentage9.44%0.03%6.03%6.80%40.90%
Miscellaneous
Employees39N/A2516720
Shares Outstanding16.01 million74.22 million11.35 million9.49 million16.34 million
Next Earnings Date5/11/2021 (Estimated)4/29/2021 (Estimated)6/29/2021 (Estimated)5/4/2021 (Estimated)5/21/2021 (Estimated)
OptionableOptionableNot OptionableNot OptionableOptionableNot Optionable
SourceHeadline
Cell Therapy Market 2020 Scope Analysis And Growth Prediction Outlook to 2026 – The Courier - The CourierCell Therapy Market 2020 Scope Analysis And Growth Prediction Outlook to 2026 – The Courier - The Courier
mccourier.com - April 8 at 4:40 PM
Should You Take Comfort From Insider Transactions At BioCardia, Inc. (NASDAQ:BCDA)? - NasdaqShould You Take Comfort From Insider Transactions At BioCardia, Inc. (NASDAQ:BCDA)? - Nasdaq
nasdaq.com - April 8 at 2:13 PM
Cell Therapy Market 2021-2027 Forecast Research Reports offers Key Insights: Dendreon, Mesoblast, Vericel, AlloCure - The CourierCell Therapy Market 2021-2027 Forecast Research Reports offers Key Insights: Dendreon, Mesoblast, Vericel, AlloCure - The Courier
mccourier.com - April 8 at 12:24 PM
Deflectable Catheters Market Report 2021 shows positive signs | Johnson & Johnson, Medtronic, Abbott - KSU | The Sentinel NewspaperDeflectable Catheters Market Report 2021 shows positive signs | Johnson & Johnson, Medtronic, Abbott - KSU | The Sentinel Newspaper
ksusentinel.com - April 8 at 11:39 AM
Myocardial Infarction Drug Market Projected to Witness a Rapid Growth by 2027, Key Players – Juventas Therapeutics, Inc., HUYA Bioscience International, LLC, LegoChem Biosciences, Inc, Immune Pharmaceuticals Inc. - KSU | The Sentinel NewspaperMyocardial Infarction Drug Market Projected to Witness a Rapid Growth by 2027, Key Players – Juventas Therapeutics, Inc., HUYA Bioscience International, LLC, LegoChem Biosciences, Inc, Immune Pharmaceuticals Inc. - KSU | The Sentinel Newspaper
ksusentinel.com - April 8 at 6:39 AM
SRNE Stock - SRNE Stock - BUZZ-US STOCKS ON THE MOVE-Infinity Pharmaceuticals, BioCardia, Caesars Entertainment, TransMedics Group | Fintech Zoom - Fintech ZoomSRNE Stock - SRNE Stock - BUZZ-US STOCKS ON THE MOVE-Infinity Pharmaceuticals, BioCardia, Caesars Entertainment, TransMedics Group | Fintech Zoom - Fintech Zoom
fintechzoom.com - April 3 at 9:47 PM
Sorrento Therapeutics, Inc. (SRNE) Stock Price, News - Fintech ZoomSorrento Therapeutics, Inc. (SRNE) Stock Price, News - Fintech Zoom
fintechzoom.com - April 3 at 9:47 PM
SRNE Stock - BUZZ-US STOCKS ON THE MOVE-Infinity Pharmaceuticals, BioCardia, Caesars Entertainment, TransMedics Group - Fintech ZoomSRNE Stock - BUZZ-US STOCKS ON THE MOVE-Infinity Pharmaceuticals, BioCardia, Caesars Entertainment, TransMedics Group - Fintech Zoom
fintechzoom.com - April 3 at 4:46 PM
Have Insiders Been Buying BioCardia, Inc. (NASDAQ:BCDA) Shares? - Yahoo FinanceHave Insiders Been Buying BioCardia, Inc. (NASDAQ:BCDA) Shares? - Yahoo Finance
finance.yahoo.com - April 1 at 10:13 AM
Have Insiders Been Buying BioCardia, Inc. (NASDAQ:BCDA) Shares?Have Insiders Been Buying BioCardia, Inc. (NASDAQ:BCDA) Shares?
finance.yahoo.com - April 1 at 7:19 AM
BioCardia Reports 2020 Financial Results and Recent Business Highlights - GlobeNewswireBioCardia Reports 2020 Financial Results and Recent Business Highlights - GlobeNewswire
globenewswire.com - April 1 at 5:13 AM
Targeted Drug Delivery Device Market 2021: Potential growth, attractive valuation make it is a long-term investment | Know the COVID19 Impact | Top Players: 4D Molecular Therapeutics, AbbVie, Abeona Therapeutics, Advaxis, Alcyone Lifesciences, etc. – KSU | The Sentinel Newspaper - KSU | The Sentinel NewspaperTargeted Drug Delivery Device Market 2021: Potential growth, attractive valuation make it is a long-term investment | Know the COVID19 Impact | Top Players: 4D Molecular Therapeutics, AbbVie, Abeona Therapeutics, Advaxis, Alcyone Lifesciences, etc. – KSU | The Sentinel Newspaper - KSU | The Sentinel Newspaper
ksusentinel.com - March 31 at 11:15 AM
Comprehensive Report on Targeted Drug Delivery Device Market 2021 | Trends, Growth Demand, Opportunities & Forecast To 2027 |4D Molecular Therapeutics, AbbVie, Abeona Therapeutics, Advaxis, Alcyone Lifesciences, etc – KSU | The Sentinel Newspaper - KSU | The Sentinel NewspaperComprehensive Report on Targeted Drug Delivery Device Market 2021 | Trends, Growth Demand, Opportunities & Forecast To 2027 |4D Molecular Therapeutics, AbbVie, Abeona Therapeutics, Advaxis, Alcyone Lifesciences, etc – KSU | The Sentinel Newspaper - KSU | The Sentinel Newspaper
ksusentinel.com - March 31 at 11:15 AM
Tencent To Buy Back $1B In Stock; Shares Gain Pre-Market - NasdaqTencent To Buy Back $1B In Stock; Shares Gain Pre-Market - Nasdaq
nasdaq.com - March 31 at 8:39 AM
BioCardia (NASDAQ:BCDA) Posts  Earnings Results, Beats Expectations By $0.15 EPSBioCardia (NASDAQ:BCDA) Posts Earnings Results, Beats Expectations By $0.15 EPS
americanbankingnews.com - March 31 at 7:50 AM
4 Stocks Poised to Gain From Uptick in Campus Networking Spend - Nasdaq4 Stocks Poised to Gain From Uptick in Campus Networking Spend - Nasdaq
nasdaq.com - March 30 at 10:38 PM
Deutsche (DB) Might File Lawsuit Against Two Ex-Madoff Funds - NasdaqDeutsche (DB) Might File Lawsuit Against Two Ex-Madoff Funds - Nasdaq
nasdaq.com - March 30 at 12:50 PM
BlackBerry (BB) QNX Software Boosts Scanias Heavy Vehicles - NasdaqBlackBerry (BB) QNX Software Boosts Scania's Heavy Vehicles - Nasdaq
nasdaq.com - March 30 at 12:37 PM
Viasat (VSAT) Arm Sets Up Facility in UK to Boost Cybersecurity - NasdaqViasat (VSAT) Arm Sets Up Facility in UK to Boost Cybersecurity - Nasdaq
nasdaq.com - March 30 at 12:37 PM
Form 10-K BioCardia, Inc. For: Dec 31 - StreetInsider.comForm 10-K BioCardia, Inc. For: Dec 31 - StreetInsider.com
streetinsider.com - March 30 at 12:37 PM
BioCardia, Inc. (BCDA) Reports Q4 Loss, Misses Revenue Estimates - Yahoo FinanceBioCardia, Inc. (BCDA) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance
finance.yahoo.com - March 30 at 12:37 PM
BioCardia Reports 2020 Financial Results and Recent Business Highlights - Yahoo FinanceBioCardia Reports 2020 Financial Results and Recent Business Highlights - Yahoo Finance
finance.yahoo.com - March 30 at 12:37 PM
BioCardia, Inc. (BCDA) Reports Q4 Loss, Misses Revenue EstimatesBioCardia, Inc. (BCDA) Reports Q4 Loss, Misses Revenue Estimates
finance.yahoo.com - March 30 at 12:36 PM
BioCardia Reports 2020 Financial Results and Recent Business HighlightsBioCardia Reports 2020 Financial Results and Recent Business Highlights
finance.yahoo.com - March 30 at 9:16 AM
BIOCARDIA, INC. : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K) - marketscreener.comBIOCARDIA, INC. : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K) - marketscreener.com
marketscreener.com - March 29 at 6:14 PM
DateCompanyBrokerageAction
3/30/2021aTyr PharmaOppenheimerBoost Price Target
3/22/2021aTyr PharmaRoth CapitalBoost Price Target
8/17/2020aTyr PharmaHC WainwrightUpgrade
8/30/2019aTyr PharmaCitigroupSet Price Target
3/26/2019aTyr PharmaWilliam BlairReiterated Rating
10/8/2018aTyr PharmaPiper Jaffray CompaniesLower Price Target
8/15/2018aTyr PharmaBMO Capital MarketsLower Price Target
1/13/2021Acorda TherapeuticsCowenBoost Price Target
8/11/2020Acorda TherapeuticsJefferies Financial GroupReiterated Rating
2/16/2020Acorda TherapeuticsJPMorgan Chase & Co.Reiterated Rating
8/2/2019Acorda TherapeuticsStifel NicolausLower Price Target
8/2/2019Acorda TherapeuticsWedbushLower Price Target
8/2/2019Acorda TherapeuticsCantor FitzgeraldLower Price Target
9/21/2020BioCardiaAlliance Global PartnersInitiated Coverage
8/14/2020BioCardiaMaxim GroupInitiated Coverage
11/26/2019BioCardiaBrookline Capital ManagementReiterated Rating
9/17/2019BioCardiaDawson JamesInitiated Coverage
(Data available from 4/10/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.